Outlook Therapeutics, Inc. (OTLK) — insider trading
Health Care · NASDAQ
Outlook Therapeutics, Inc. (OTLK) has 29 reported SEC Form 4 insider transactions in our data, including 16 open-market purchases among the most recent 29 (latest 2026-09-01).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | Lundquist Kevin Michael | Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 500,000 | — | $0 | Form 4 |
| 2026-08-14 | KENYON LAWRENCE A | Director, Officer (Chief Financial Officer) | Open-market purchase (derivative) | 101,010 | — | — | Form 4 |
| 2026-08-14 | KENYON LAWRENCE A | Director, Officer (Chief Financial Officer) | Open-market purchase | 101,010 | — | — | Form 4 |
| 2026-08-14 | Jahr Robert Charles | Director, Officer (Chief Executive Officer) | Open-market purchase (derivative) | 151,515 | — | — | Form 4 |
| 2026-08-14 | Jahr Robert Charles | Director, Officer (Chief Executive Officer) | Open-market purchase | 151,515 | — | — | Form 4 |
| 2026-08-12 | Sukhtian Ghiath M.; GMS Ventures & Investments | Director, 10% owner | Open-market purchase (derivative) | 2,525,252 | — | $0 | Form 4 |
| 2026-08-12 | Sukhtian Ghiath M.; GMS Ventures & Investments | Director, 10% owner | Open-market purchase | 2,525,252 | $0.99 | $2.50M | Form 4 |
| 2026-07-29 | Sukhtian Faisal Ghiath | Director | Open-market purchase | 95,398 | $1.05 | $100.0K | Form 4 |
| 2026-07-21 | Jahr Robert Charles | Director, Officer (Chief Executive Officer) | Grant / award / vesting (derivative) | 100,000 | — | $0 | Form 4 |
| 2026-07-21 | KENYON LAWRENCE A | Director, Officer (Chief Financial Officer) | Grant / award / vesting (derivative) | 210,078 | — | $0 | Form 4 |
| 2026-06-02 | Haddadin Yezan Munther | Director | Open-market purchase | 29,000 | $0.8326 | $24.1K | Form 4 |
| 2026-05-28 | Sukhtian Ghiath M.; GMS Ventures & Investments | Director, 10% owner | Open-market purchase (derivative) | 8,571,428 | — | — | Form 4 |
| 2026-05-28 | Sukhtian Ghiath M.; GMS Ventures & Investments | Director, 10% owner | Expiration of long derivative position (derivative) | 8,571,428 | — | — | Form 4 |
| 2026-05-28 | Sukhtian Ghiath M.; GMS Ventures & Investments | Director, 10% owner | Open-market purchase (derivative) | 3,458,571 | — | — | Form 4 |
| 2026-05-28 | Sukhtian Ghiath M.; GMS Ventures & Investments | Director, 10% owner | Expiration of long derivative position (derivative) | 3,458,571 | — | — | Form 4 |
| 2026-05-28 | Sukhtian Ghiath M.; GMS Ventures & Investments | Director, 10% owner | Open-market purchase (derivative) | 3,458,571 | — | — | Form 4 |
| 2026-05-28 | Sukhtian Ghiath M.; GMS Ventures & Investments | Director, 10% owner | Expiration of long derivative position (derivative) | 3,458,571 | — | — | Form 4 |
| 2026-05-28 | Sukhtian Ghiath M.; GMS Ventures & Investments | Director, 10% owner | Open-market purchase | 8,539,709 | $0.5855 | $5.00M | Form 4 |
| 2026-05-27 | Sukhtian Faisal Ghiath | Director | Open-market purchase | 122,174 | $0.4093 | $50.0K | Form 4 |
| 2026-05-26 | HILZINGER KURT J | Director | Open-market purchase | 400,000 | $0.4413 | $176.5K | Form 4 |
| 2026-05-26 | THURMAN RANDY H | Director | Open-market purchase | 5,000 | $0.429 | $2.1K | Form 4 |
| 2026-05-26 | Haddadin Yezan Munther | Director | Open-market purchase | 34,000 | $0.44 | $15.0K | Form 4 |
| 2025-10-03 | HILZINGER KURT J | Director | Grant / award / vesting (derivative) | 90,638 | — | $0 | Form 4 |
| 2025-10-03 | Haller Julia A | Director | Grant / award / vesting (derivative) | 58,648 | — | $0 | Form 4 |
| 2025-10-03 | Huang Andong | Director | Grant / award / vesting (derivative) | 53,316 | — | $0 | Form 4 |
| 2025-10-01 | Gangolli Julian S | Director | Grant / award / vesting (derivative) | 286,734 | — | $0 | Form 4 |
| 2025-10-01 | HILZINGER KURT J | Director | Grant / award / vesting (derivative) | 286,734 | — | $0 | Form 4 |
| 2025-10-01 | Haller Julia A | Director | Grant / award / vesting (derivative) | 286,734 | — | $0 | Form 4 |
| 2025-10-01 | Huang Andong | Director | Grant / award / vesting (derivative) | 286,734 | — | $0 | Form 4 |
Ask the chat about OTLK's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Outlook Therapeutics, Inc. (OTLK).
Last updated 2026-09-01 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.